Are NAD+ injections better than oral NMN or NR?

Injections and IV infusions have thinner controlled-trial support than oral precursors, not stronger. The bioavailability argument for injecting is real chemistry, but higher blood levels are the same surrogate endpoint the oral trials already achieved without producing consistent clinical benefit. Injections cost several times more.

How much do NAD+ supplements cost?

Oral precursors run roughly $39 to $80 a month. Self-administered injection programmes run about $130 to $263 a month all-in once membership fees are counted, and in-person IV infusions run $250 to $1,000 per session.

Longevity · Evidence

Do NAD+ supplements actually work?

Q: Do NAD+ supplements actually work?

Oral NR and NMN reliably raise blood NAD+, roughly doubling it. That biomarker change has not translated into consistent clinical benefit: a meta-analysis of NMN trials found most glucose and lipid outcomes no different from control, and a review of human NR trials found largely null results on cognitive, vascular and metabolic endpoints. No human trial shows a lifespan or aging-rate benefit.

The honest answer has two halves, and the marketing only ever tells you the first one. Yes, these compounds do the biochemical thing they claim. No, that has not yet been shown to make you healthier.

Prices researched 2026-09-06 · evidence sourced below · journalism, not medical advice · every NAD+ channel priced

The one-paragraph version. Oral NR and NMN reliably raise blood NAD+ (roughly doubling it), but that biomarker change has not translated into consistent clinical benefit in human trials: meta-analysis of NMN RCTs found most glucose/lipid outcomes no different from control, and a review of human NR trials found largely null results on cognition, vascular and metabolic endpoints. No human trial shows a lifespan or aging-rate benefit. Injections and IVs have thinner controlled-trial support than oral precursors. These prices buy a validated biomarker change, not a validated health outcome.

The surrogate-endpoint problem, in plain English

A surrogate endpoint is a measurement that stands in for the thing you actually care about. Blood NAD+ is a surrogate. Living longer, thinking more clearly, or having better blood sugar are the real endpoints.

NAD+ precursors clear the surrogate convincingly — oral NR and NMN roughly double circulating NAD+, and that is not in dispute. The gap is what happens next. When trials went on to measure cognition, vascular function and metabolic markers, the results were largely null. A meta-analysis of NMN randomised trials found most glucose and lipid outcomes no different from control.

This pattern is common enough in medicine to have a name. Raising HDL cholesterol looked like a guaranteed win for decades; drugs that did it reliably failed to reduce heart attacks. A number moving in the right direction is a reason to run the trial, not a substitute for having run it.

What each claim is actually supported by

The claim	What the human evidence supports
"Raises your NAD+ levels"	Supported. Roughly a doubling of blood NAD+ with oral NR or NMN. This is the claim the trials do back.
"Improves metabolic health"	Not supported. Meta-analysis of NMN trials found most glucose and lipid outcomes no different from control.
"Sharper thinking, better energy"	Not supported. A review of human NR trials found largely null results on cognitive endpoints.
"Slows aging" / "extends lifespan"	No human trial shows a lifespan or aging-rate benefit. The animal work that drives this claim has not replicated into people.
"Injections work better than pills"	Backwards, on the evidence. Injections and IVs have thinner controlled-trial support than oral precursors, not stronger.

The injection question specifically

The argument for injecting is real chemistry: oral NMN is partly broken down before absorption, so bypassing the gut delivers more. But notice what that argument optimises for — a higher level of the surrogate. The oral trials already achieved the surrogate and still did not produce consistent clinical benefit. Getting further along a road that has not been shown to lead anywhere is not obviously progress, and it costs several times more.

Route	Typical cost	Controlled-trial support
Oral NR / NMN	~$39–$80/month	The strongest of a weak field: surrogate confirmed, clinical endpoints largely null
Self-injection programmes	~$130–$263/month all-in	Thinner than oral
In-person IV infusion	$250–$1,000 per session	Thinnest; loading courses run $1,200–$8,000

Cost rows are drawn from the same dataset as the priced market tables, where every row carries its source and a listed-or-reported status.

If you are going to buy anyway

Plenty of people will read all of the above and still want to try it, which is a legitimate choice with their own money. In that case the useful questions are about not overpaying for the same molecule:

Price per gram, not price per bottle. Doses across these products range from 300 mg to 1,000 mg a day, so bottle prices are not comparable. The cheapest oral option we track is Tru Niagen at $39.20/mo subscription ($49 one-time).
NR and NMN are different molecules with separate evidence bases. Marketing frequently blurs them, and a trial of one is not a trial of the other.
"Liposomal", "enhanced absorption" and similar are absorption claims — surrogate claims again. They are not clinical-outcome claims, whatever the packaging implies.
Watch the subscription cadence. Several sellers advertise a subscription price and bill on a shorter interval than a month, which is the same billing pattern we document across telederm.
These are supplements, not approved drugs. No FDA review of efficacy stands behind any of them, and manufacturing quality is not verified the way a prescription medicine's is.

What would change our answer

A well-powered randomised trial with a clinical endpoint — not a biomarker — showing benefit in people. That trial has not been run at the scale the market implies. If it lands, this page changes the same day and the correction appears in our changelog.

Watch: the NAD+ evidence debate

Independent third-party material we found genuinely useful. Embedding is not endorsement, we have no relationship with these creators, and any commercial conflicts we know of are labelled. Videos load only when you press play.

NAD and NAD precursors: help or hype?

Peter Attia, MD · with Matt Kaeberlein, PhD, biogerontologist · 2021-09-17

Two credentialed people examining why the NAD+ evidence is thinner than the marketing — the honest counterweight to this market.

disclosureAttia runs a paid membership and has supplement-industry ties; he sells no NAD+ product and is skeptical here.

Potential Risks of NAD Supplements

Peter Attia, MD · with Iñigo San-Millán, PhD · 2022-04-02

The risk side of NAD+ supplementation, rarely covered by sellers.

disclosurePaid membership; supplement-industry ties.

Sources

www.tandfonline.com — https://www.tandfonline.com/doi/full/10.1080/10408398.2024.2387324
www.science.org — https://www.science.org/doi/10.1126/sciadv.adi4862
iadns.onlinelibrary.wiley.com — https://iadns.onlinelibrary.wiley.com/doi/10.1002/fft2.511

Keep reading: Every NAD+ channel priced · NAD+ precursors: the medication file · Longevity interventions in evidence order · What diet actually does for healthspan

Evidence journalism, not medical advice, and not a recommendation for or against any supplement. NAD+ precursors are sold as dietary supplements and are not FDA-approved to treat or prevent anything. Absence of demonstrated benefit is not the same as demonstrated harm — it means the question is open. If you take medication or have a health condition, that conversation belongs with a clinician who can see your history.